Beta blocker use was associated with reduced mortality (HR 0.63, p=0.03) in patients hospitalized with heart failure, while tachycardia and NYHA class IV predicted increased mortality.
Cohort (n=1,223)
What are the predictors of mortality in patients hospitalised with heart failure?
In patients hospitalized with heart failure, beta-blocker use is associated with improved survival, whereas tachycardia and NYHA class IV are significant independent predictors of mortality.
Hazard Ratio: 0.63
p-value: p=0.03
OBJECTIVES: Heart failure (HF) has a high rate of hospitalisation and mortality. We examined its risk factors, survival rate and the predictors. METHODS: In this prospective cohort study, demographic, clinical and treatment data of 1223 patients hospitalised with HF were extracted from the Persian Registry Of cardio Vascular diseasE (PROVE)/HF registry. Survival rate and HR and their association with other variables were assessed. RESULTS: 835 (68.3%) were censored, while 388 (31.7%) patients were deceased. Mean age and frequency of hypotension during hospitalisation, tachycardia, pulmonary hypertension and anaemia, hyponatremia, heart valve disease and renal disease of the deceased patients was significantly higher than censored patients (15.2vs6.1%, 51.1vs40.1%, 24.4vs16.7%, 39.0vs31.8%, respectively, p1) and using ACEI/ARB and BB as predictors of life (HR <1, p<0.05). After adjustment, all variables lost their significance, except BB (HR 0.63, p=0.03) and tachycardia (HR 1.74, p=0.01) and New York Heart Association (NYHA) class IV (HR 1.90, p=0.04) became significant predictors. CONCLUSIONS: We found a high mortality rate (31.7%). As NYHA class IV and tachycardia were significant predictors of mortality after adjustment, an effective measure can be treatment of underlying diseases, which deteriorate patients' conditions. Monitoring of medications for at-risk group, especially BB that predicts life, is important.
Givi et al. (Fri,) conducted a cohort in Heart failure (n=1,223). Beta blocker use vs. Non-use was evaluated on Mortality (HR 0.63, p=0.03). Beta blocker use was associated with reduced mortality (HR 0.63, p=0.03) in patients hospitalized with heart failure, while tachycardia and NYHA class IV predicted increased mortality.